Mark E. Dmytruk sold $9,948 of DNA
See remarks at Ginkgo Bioworks Holdings, Inc.. 740 shares at an average of $13.44, traded Feb 4, 2025, filed Feb 6, 2025.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- 0Share of holdings soldSold 2.1% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-25-003436, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 3, 2025 | MOption exercise Class A Common Stock | +454 | - | - | 33,670 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Class A Common Stock | +453 | - | - | 34,123 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Class A Common Stock | +572 | - | - | 34,695 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Class A Common Stock | +8 | - | - | 34,703 | Feb 6, 2025 |
| Feb 4, 2025 | SOpen-market sale Class A Common Stock | -740 | $13.44 | $9,948 | 33,963 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Restricted Stock Unitsderivative | -454 | - | - | 4,976 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Restricted Stock Unitsderivative | -453 | - | - | 11,329 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Restricted Stock Unitsderivative | -572 | - | - | 21,204 | Feb 6, 2025 |
| Feb 3, 2025 | MOption exercise Class B Common Stockderivative | -8 | - | - | 15,411 | Feb 6, 2025 |
Related signals
Other insiders at Ginkgo Bioworks Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $36k 2,403 shares | -5% | |
| 26Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Christian O Henry director | $35k 5,000 shares | -21% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $2,624 346 shares | -4% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Mark E. Dmytruk See remarks | $5,355 706 shares | -2% | |
| 13Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $7,261 997 shares | -10% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Mark E. Dmytruk See remarks | $9,060 1,244 shares | -3% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $3,051 395 shares | -5% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Mark E. Dmytruk See remarks | $6,103 790 shares | -2% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $4,934 367 shares | -5% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $3,797 324 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.